Results 51 to 60 of about 16,507 (152)

Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists

Vascular Health and Risk Management, 2017
Juan Carlos Yugar-Toledo,1 Rodrigo Modolo,2 Ana Paula de Faria,2 Heitor Moreno2 1São José do Rio Preto Medicine School – FAMERP, São José do Rio Preto, 2School of Medical Sciences, University of Campinas (UNICAMP ...
Yugar-Toledo JC, Modolo R, de Faria AP, Moreno H   +3 more
doaj  

Clinical application of mineralocorticoid receptor antagonists in chronic heart failure

Медицинский совет, 2014
The review of literature discusses pathogenetic aspects of chronic heart failure and post-infarction remodelling in the heart. The focus is on the role of neurohormonal activation and the important role of aldosterone.
MG Bubnova
doaj   +1 more source

Finerenone: a game changer for chronic kidney disease patients with type 2 diabetes

Journal of the Pakistan Medical Association
Dear Editor, Type 2 diabetes or (T2D) is characterized by the elevated blood glucose levels resulting from impaired beta-cell function and insulin resistance.
Fizzah Ikram Ul Haq, Aaitain Ikram Ul Haq   +1 more
doaj   +1 more source

A short review of primary aldosteronism in a question and answer fashion

Endocrine Regulations, 2018
Objectives. The aim of this study was to present up to date information concerning the diagnosis and treatment of primary aldosteronism (PA). PA is the most common cause of endocrine hypertension.
Farrugia Frederick-Anthony, Zavras Nicolaos, Martikos Georgios, Tzanetis Panagiotis, Charalampopoulos Anestis, Misiakos Evangelos P., Sotiropoulos Dimitrios, Koliakos Nikolaos   +7 more
doaj   +1 more source

Contemporary Guideline‐Directed Medical Therapy for Heart Failure in the United States: The EMPACE Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Randomized trials and clinical guidelines support early initiation of guideline‐directed medical therapy (GDMT) for heart failure (HF). The EMPACE (Treatment Patterns of Guideline‐Directed Medical Therapies in Heart Failure Patients in the ...
Stephen J. Greene, Atif Adam, Niklas Schmedt, Christian Carlsen, Milou Brand, Eleanor Davies, Laurence Sophie Jouaville Abrouk, Juergen H. Prochaska, Phuong Tran, Ayman Alhamdow   +9 more
doaj   +1 more source

Mineralocorticoid receptors in the pathophysiology of vascular inflammation and atherosclerosis.

Frontiers in Endocrinology, 2015
Atherosclerosis is a chronic inflammatory disease of the vasculature that causes significant morbidity and mortality from myocardial infarction, stroke, peripheral vascular disease, and heart failure.
Mary Elizabeth Moss, Mary Elizabeth Moss, Iris Z Jaffe, Iris Z Jaffe   +3 more
doaj   +1 more source

Mineralocorticoid receptor antagonists: their use and differentiation in Japan [PDF]

Hypertension Research, 2012
In the presence of salt, aldosterone causes hypertension and organ damage via the mineralocorticoid receptor (MR) through various mechanisms. MR antagonists are considered to be potassium-sparing diuretics that exert their effect by blocking MR in the kidney, and they are not the first choice for treating hypertension.
openaire   +2 more sources

Mineralocorticoid Receptor Antagonists in Dialysis

American Journal of Nephrology
Background: Aldosterone regulates genes controlling fluid and electrolyte balance through mineralocorticoid receptor (MR) activation. Sustained MR activation promotes inflammation, fibrosis, sodium retention, and myocardial remodeling. MR antagonists (MRAs) block aldosterone binding in the kidney, heart, and vasculature and are classified as steroidal ...
Elias John Elenjickal, Thomas A. Mavrakanas   +1 more
openaire   +1 more source

Mineralocorticoid receptor antagonists in heart failure with preserved (and mildly reduced) ejection fraction: a comparative review of spironolactone and finerenone

Global Cardiology
Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all heart failure presentations and remains associated with substantial mortality, ranging from 15% at 1 year to nearly 75% within 5-10 years following ...
Hafsa Azam, Syed Sarmad Javaid, Mahir Karakas   +2 more
doaj   +1 more source

Care and Outcomes of New‐Onset Heart Failure Across Vulnerable Populations: Temporal Trends in Mortality and Treatment in a Danish Nationwide Cohort From 2003 to 2022

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Heart failure (HF) prevalence is increasing. In a nationwide cohort study, we investigated temporal trends in care and outcomes of patients with new‐onset HF within vulnerable populations.
Sofie‐Louise Feentved Ødum, Clara Friis, Caroline Hartwell Garred, Nina Nouhravesh, Deewa Zahir Anjum, Camilla Fuchs Andersen, Jesper Jensen, Emil Fosbøl, Lars Køber, Daniel Mølager Christensen, Marte Austreim, Morten Malmborg, Morten Schou, Mariam Elmegaard   +13 more
doaj   +1 more source